JP Morgan Put 150 CHKP 18.10.2024/ DE000JK2H7K9 /
9/20/2024 10:35:21 AM | Chg.+0.003 | Bid10:00:30 PM | Ask10:00:30 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.011EUR | +37.50% | - Bid Size: - |
- Ask Size: - |
Check Point Software... | 150.00 USD | 10/18/2024 | Put |
GlobeNewswire
9/3
Check Point Software Unveils New MSSP Portal for Partners: Vastly Simplifying Service Delivery and E...
GlobeNewswire
8/30
Carahsoft Sponsors 15th Annual Billington Cybersecurity Summit in Washington, D.C. on September 3-6...
GlobeNewswire
8/28
Mestag Therapeutics Awarded Significant Grant from Innovate UK’s Prestigious Cancer Therapeutics Pro...
GlobeNewswire
8/28
BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire
8/27
Check Point Software to Acquire Cyberint to Transform Security Operations and Expand Managed Threat ...
GlobeNewswire
8/14
Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update
GlobeNewswire
8/14
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
GlobeNewswire
8/13
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
8/13
Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
GlobeNewswire
8/13
PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results
GlobeNewswire
8/13
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
8/12
Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024...
GlobeNewswire
8/12
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in C...
GlobeNewswire
8/12
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
GlobeNewswire
8/8
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
8/8
Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress
GlobeNewswire
8/8
PDS Biotech Announces Abstract Accepted for Oral Presentation at 2024 ASTRO Annual Meeting
GlobeNewswire
8/8
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update